Search
Filter Results
Displaying 11–20 of 42 for “XLRP”
-
XLRP-Patient Focused Drug Development
The goal of the June 7th meeting will be to educate FDA staff and other key stakeholders such as biotech and pharmaceutical companies about what it is like to live with XLRP, with perspectives from both affected individuals as well as caregivers and family members of affected individuals.
-
Jul 22, 2020
AGTC Planning Phase 2/3 Clinical Trial for XLRP Gene Therapy
The company is also expanding its Phase ½ trial for the emerging treatment
-
Feb 27, 2020
Researchers Report Six-Month Results from Biogen-Sponsored XLRP Gene Therapy Clinical Trial
Vision improvements observed with medium and high doses
-
Live Stream: XLRP-Patient Focused Drug Development
The live meeting will be to educate FDA staff and other key stakeholders such as biotech and pharmaceutical companies about what it is like to live with XLRP, with perspectives from both affected individuals as well as caregivers and family members of affected individuals.
-
Apr 25, 2022
Webinar for the X-Linked Retinitis Pigmentosa (XLRP) Community
The Foundation Fighting Blindness recently held a webinar to provide details about an upcoming Externally-Led Patient Focused Drug Development (EL-PFDD) meeting for XLRP, and to provide background information about the Food and Drug Administration’s (FDA) drug review process.
-
Sep 24, 2021
MeiraGTx and Janssen Recruiting for Phase 3 XLRP Gene Therapy Clinical Trial
Visit www.LUMEOSstudy.com for more information about trial
-
Jun 12, 2023
Beacon Therapeutics to Advance XLRP, Cone-Rod Dystrophy, and Dry AMD Gene Therapies
An emerging XLRP gene therapy acquired from AGTC is the company’s lead clinical program
-
Aug 4, 2015
A Surprising Number of Carrier Females are Affected by X-Linked Retinitis Pigmentosa
40 percent of genetically tested XLRP carriers showed a definitive abnormality in at least one of three visions tests.
-
Jan 18, 2022
Survey results will inform therapy developers and the agenda for a Patient-Focused Drug Development meeting with Food and Drug Administration representatives.
-
Dec 21, 2018
Applied Genetic Technologies Corporation (AGTC), a leading developer of gene therapies, has reported the six-month follow-up data in all patients treated with its gene therapy for X-linked retinoschisis (XLRS) in its Phase I/II clinical trial.